Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges
- 13 August 2020
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Clinical Pharmacology
- Vol. 13 (9), 957-975
- https://doi.org/10.1080/17512433.2020.1805315
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has spread globally since it outbroke in December 2019. The urgent pandemic presents an unprecedented challenge to develop and identify effective medication therapy strategies to combat the COVID-19. Here, we summarized and evaluated the current treatment drugs and regimens, and put forward the treatment recommendations, including using the potential repurposed or experimental drugs against COVID-19, e.g., chloroquine (CQ), hydroxychloroquine (HCQ), lopinavir/ritonavir (LPV/r), remdesivir (RDV), favipiravir (FPV). We also analyzed the specific drugs and vaccines against SARS-CoV-2 ongoing development and formulated the comprehensive treatment regimens based on condition of patients, diseases and drugs as well as concomitant medications. No drugs and vaccines have been proven to be particularly effective against SARS-CoV-2 up to now. The recommended comprehensive medication therapy strategies have already displayed favorable effect in the fight against COVID-19. Research should be focused on the development of anti-SARS-CoV-2 drugs and vaccines based on high-quality clinical trial evidence, treatment guidelines and expert consensus.Keywords
Funding Information
- National Natural Science Funds of China (81873078, 81374051)
This publication has 100 references indexed in Scilit:
- Beneficial effects of fluid resuscitation via the rectum on hemodynamic disorders and multiple organ injuries in an experimental severe acute pancreatitis modelPancreatology, 2015
- Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common MarmosetThe Journal of Infectious Diseases, 2015
- Chalcones isolated fromAngelica keiskeiinhibit cysteine proteases of SARS-CoVJournal of Enzyme Inhibition and Medicinal Chemistry, 2015
- Exosomes Derived from Mesenchymal Stem CellsInternational Journal of Molecular Sciences, 2014
- Arbidol inhibits viral entry by interfering with clathrin-dependent traffickingAntiviral Research, 2013
- Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's diseaseNeurobiology of Disease, 2012
- Treatment of Severe Acute Respiratory Syndrome With GlucosteroidsSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2006
- Treatment of severe acute respiratory syndromeEuropean Journal of Clinical Microbiology & Infectious Diseases, 2005
- Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitorsThe Lancet, 2004
- Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findingsThorax, 2004